This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio

Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI ) is one of the top penny stocks to buy in investors’ stock portfolio . On May 7, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) affirmed a strong start to the year, driven by strong demand in the core TriLink base business and strength in the higher-margin portfolio.

Increased focus on cost structure and operational efficiency helped the company achieve robust revenue growth and meaningful EBITDA expansion in the first quarter. Revenue in the first quarter was up 40.5% to $65.8 million, driven by a 65.1% increase in TriLink revenue at $47.5 million. Maravai LifeSciences Holdings benefited from high-volume CleanCap orders for commercial-phase COVID vaccine programs.

Net loss in the quarter shrank to $6.4 million, compared with $52.9 million in the same quarter last year. The company also bounced back to adjusted EBITDA of $20.3 million, compared with a loss of $10.5 million in the same quarter last year. For the full year, the company expects revenue to range from $205 million to $215 million, up from its previous guidance of $200 million to $210 million.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a global life sciences company that provides critical reagents and services to researchers and biotech innovators to enable the development of drug therapies, vaccines, cell and gene therapies, and diagnostics.

While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks .